The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Researchers from the University of Cincinnati filed for protection of an electrochemical aptamer-based biosensor technology ...

It's the longest-lasting wearable on the market. The G7 15-day sensor builds on the technology and performance of the Dexcom G7 CGM, which has proven to lower A1C and reduce hyper- and hypoglycemia.

As Healio previously reported, the Dexcom G7 CGM was cleared in December 2022 for people aged 2 years and older with type 1 and type 2 diabetes. Each sensor for the current-generation device can ...

Continuous Glucose Monitoring (CGM) is gaining attention as a tool for optimising dietary counselling in athletes. By ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience ...

Abbott's FreeStyle Libre continuous glucose monitoring system (CGM) has seen significant growth, with sales surpassing $1.8 billion in the fourth quarter of 2024, marking nearly 22.7% increase ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun ...